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ABSTRACT
Bacteriophages for Treating American Foulbrood and the
Neutralization of Paenibacillus larvae Spores
Thomas Scott Brady
Department of Microbiology and Molecular Biology, BYU
Master of Science
The causative agent of the most devastating honeybee disease, American foulbrood
(AFB), is the spore-forming bacterium Paenibacillus larvae. To prevent AFB outbreaks
beekeepers prophylactically treat their hives with antibiotics even though it decreases the overall
health of uninfected hives. A new treatment for AFB is needed due to recent legislation against
using antibiotics, antibiotic resistance developing in P. larvae, and the resilience of P. larvae
spores. Bacteriophages, or phages, are an attractive alternative to traditional antibiotics because
of their specificity and ability to evolve alongside their target bacterium. In this study, two phage
cocktails were developed for the treatment of AFB. The first cocktail was comprised of
Brevibacillus laterosporus phages. B. laterosporus is a commensal microbe in most honeybee
guts. When treated with B. laterosporus phages, B. laterosporus is induced to produce an
antimicrobial toxin to which P. larvae is highly sensitive. Treating AFB infected hives with B.
laterosporus phages was able to clear active infections at a rate of 75% as opposed to untreated
hives that did not recover. However, B. laterosporus phages did not clear latent P. larvae spores
and recovered hives relapsed after treatment. The second cocktail was comprised of P. larvae
phages and hives treated with the second cocktail recovered at a rate of 100%, protected 100% of
at-risk hives, and treated hives did not relapse with AFB suggesting neutralization of P. larvae
spores. A P. larvae phage used in the second cocktail was examined to identify any spore-phage
interactions. Results from modified plaque assays, fluorescence from FITC-labeled phages
bound to spores, and electron microscopy images all confirm that phages bind to P. larvae
spores. Phage therapy for the treatment of AFB is an exciting avenue not only as an alternative to
chemical antibiotics, but rather a treatment that can neutralize P. larvae spores.

Keywords: Paenibacillus larvae, American foulbrood, spores, phage therapy, honeybees,
Brevibacillus laterosporus, antimicrobial toxin, bacteriophage, phage binding
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SPECIFIC AIMS
Aim 1: Identify the effectiveness of bystander phage therapy as a treatment for AFB.
1. Generate a phage cocktail that hits a wide range of B. laterosporus that also induce toxin
production in the bacterium.
2. Test the phage cocktail on uninfected hives to observe any adverse effects of removing B.
laterosporus from hives and treat AFB infected hives to gauge ability to treat vegetative
bacteria as well as latent spores.
Aim 2: Identify the effectiveness of traditional phage therapy as a treatment for AFB.
1. Generate a phage cocktail that affects a wide range of P. larvae strains.
2. Test the phage cocktail on uninfected hives to observe any adverse effects in comparison
to prophylactic antibiotic treatments and treat AFB infected hives to gauge ability to treat
vegetative bacteria as well as latent spores.
Aim 3: To determine the relationship between P. larvae phages and P. larvae spores.
1. Prepare a stock of pure P. larvae spores on which experiments involving phage binding
can be performed.
2. Develop assays that quantify the binding of P. larvae phages to spores in relation to
related and unrelated bacteria.
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INTRODUCTION
1.1

American foulbrood: a significant threat to honeybees
American foulbrood (AFB) is the most devastating bacterial disease in honeybees (1).

AFB was first distinguished from European foulbrood in 1907 and has since been identified on
all inhabited continents (2-5). The firmicute that causes AFB, Paenibacillus larvae, is a sporeforming facultative anaerobe that only germinates from spore form in the gut of honeybee larvae
(6-10). The spores do not affect adult honeybees as they do not germinate in their guts, however,
spores can accumulate in the gut of nurse bees; inadvertently passing the spores on to larval
honeybees during feeding (11-13). The spores germinate and become vegetative (8), rapidly
divide, and produce chitinase, an enzyme that degrades larval exoskeleton, resulting in the death
and liquefaction of the larvae (6,14). Nurse bees clean the spore-laden slurry and spread the
spores as they feed the rest of the brood. Within a week without treatment, an active AFB
infection results in the collapse of an infected hive (3,15). The collapse of hives allows robber
bees from other hives to steal spore-contaminated honey, which allows for rapid spread of the
disease within an apiary. The only way to ensure no reinfection by latent spores requires
beekeepers to burn affected hive boxes and tools (16). Other methods for decontaminating
beekeeping supplies such as gamma radiation and portable autoclaves show promise but are not
yet practical and do not save the honeybees (1,17,18). P. larvae spores can survive for decades in
hive boxes and will build up in a hive over time and cause seemingly spontaneous outbreaks
(9,10,13).
Current treatments for American foulbrood are harmful to honeybees and are becoming
ineffectual. It is common practice for beekeepers to dose their hives with antibiotics to prevent
brood diseases. The antibiotics do not harm P. larvae spores but can kill susceptible vegetative
2

bacteria. There are two protein synthesis antibiotics used on honeybee hives; terramycin (a
tetracycline) and tylosin (a macrolide), which are typically administered prophylactically to
beehives in the spring and fall to prevent outbreaks. Antibiotic use causes the overall health of
treated hives to diminish by altering honeybee gut microbiota (19-21). Furthermore, tylosin
degrades into a secondary antibiotic, desmycosin, which remains in hives for years longer than
tylosin contaminating honey of treated hives (22,23). However, many P. larvae strains are now
resistant to terramycin due to overuse and recently strains have been isolated that are resistant to
tylosin (24-29).
1.2

Phages as an alternative to conventional antibiotics
Bacteriophage cocktails are an exciting alternative to chemical antibiotics for the

treatment of American foulbrood. Bacteriophages, or phages, are viruses that infect and can kill
bacteria. Phages use tail fibers to attach to specific receptors on the surface target bacteria and
inject their DNA into the bacterial cell. Once infected, the bacterial cell begins to transcribe and
replicate the phage genome by hijacking the bacterium’s energy and protein synthesis equipment
to generate more phages. Lytic phage proteins lyse the bacterium after generating progeny,
killing the bacterial cell. Phages naturally only target one species of bacteria and are often
limited to a small number of strains within that species (30-32). Some phages produce enzymes
on their tail fibers or tail fiber sheaths that are active against specific polysaccharides or proteins
to allow the phage to inject its DNA into a target cell (33,34). Due to this host selectivity, phages
cannot infect anything else – that is to say they cannot infect plants, animals, insects, or even
non-target bacteria, such as commensal bacteria present in the gut of honeybees.
Using phages to treat bacterial disease is not a new idea. Félix d’Herelle, credited with
the discovery of phages, recognized their potential as a treatment of bacterial infections and
3

employed them in the world’s first documented phage therapy in 1919 against Salmonella
gallinarum in rural France (35). Since then, the popularity of phage therapies has waxed and
waned through time and geography, remaining popular in the former Soviet Republic of Georgia
for the past 80 years (36). In the face of increasing antibiotic resistance in bacteria, phage
therapies have become an attract alternative. Today, phage cocktail therapies have been shown to
be safe and effective for treating many bacterial infections incuding E. coli infections in humans,
E. amylovora in fruit orchards, and with P. larvae infections in honeybees (36-39).
Honeybees benefit from phage specificity because other gut bacteria are not affected,
unlike antibiotic treatments that can increase the chances of fungal infections, nosema, due to
disruption of the normal balance of bacteria in the bee gut (20,40-42). Bee keepers typically
apply two to four treatments of antibiotics to their hives prophylactically to prevent AFB
infections, decreasing the overall health of their hives (43). However, in 2016 the FDA banned
prophylactic antibiotics, requiring beekeepers to obtain a prescription from a veterinarian in
order to dose their bees (44). This highlights the need for an effective alternative to traditional
antibiotics such as phage therapy.
1.3

Phages binding to bacterial spores
Research involving phages that target Bacillus anthracis and Bacillus subtilis has shown

interesting results for phages that bind to spores. In 2003, researchers used modified E. coli
phages to biopan for phages that are selective for Bacillus spores (45). They identified phages
that selectively bound Bacillus spores and from those derived phages with high affinity for B.
subtilis and B. anthracis spores (46). Subsequent research has shown that the phages for B.
anthracis can be used as bio-markers to ascertain the presence of spores. In 2003, a research
team isolated naturally occurring phages using a mixed lysate biopanning method to identify
4

them. They discovered that the isolated phages are active against vegetative B. anthracis and
tested their ability to decontaminate surfaces with B. anthracis spores. They found that the
phages where able to kill the spores after germination, effectively decontaminating certain
surfaces (47). In 2011, the same researchers characterized the mechanism by which the sporebinding phage 8a inserts its DNA into B. anthracis spores (48). These successes with sporebinding phages leave a pattern that can now be followed while approaching P. larvae sporebinding phages.
We hypothesize that spores can be covered with phages and then, upon spore
germination, the bound phages can inject their DNA to replicate in the now vegetative cell. If
conditions allow for phage neutralization of P. larvae bacterial spores, then treatment with
phages will be an even more powerful method of preventing AFB. Phages that neutralize spores
could lead to a future treatment of AFB-contaminated hive components and equipment as well as
a long-acting preventative treatment for AFB. If the phages that target P. larvae do not neutralize
the spores, then a limit on the effectiveness of the phage cocktail treatment can be set.
1.4

Brevibacillus laterosporus bystander phage therapy
Bystander phage therapy using Brevibacillus laterosporus as a target is another method

by which phages could be used to treat AFB. B. laterosporus is a ubiquitous bacterium found in
soil, milk, cheese, and insect bodies, the most notable of which being honeybees (49). B.
laterosporus is a spore-forming firmicute and is genetically similar to P. larvae, both belonging
to the family Paenibacillaceae. The role of B. laterosporus in honeybee hives is not well
understood. Some studies report that B. laterosporus is a probiotic that increases brood
production, prevents disease, and can treat brood diseases while others show that B. laterosporus
causes minor disease after a primary infection (50-53). B. laterosporus is a known pathogen of
5

many insects of the order Diptera (honeybees belong to the order Hymenoptera) including
common houseflies and mosquitoes and has been used as an insect biocontrol with moderate
success (54-59). At least twelve toxins have been identified and classified in B. laterosporus that
have insecticidal and antimicrobial properties (49). When B. laterosporus is challenged with B.
laterosporus phages the bacterium begins to produce high levels of antimicrobials. P. larvae is
very sensitive to these phage-induced toxin. These findings led us to believe that the creation of a
phage cocktail against B. laterosporus could be used as a ‘bystander phage therapy’ where the
phages do not directly infect and kill the pathogen. Bystander phage therapy could the bridge
between normal phage therapy and antibiotic use but this hypothesis requires further
investigation.
1.5

Summary of chapters 2-4
The following chapters are copies of articles that are published or under review. Chapter

2 follows our investigation into the toxicity of phage-induced toxins produced B. laterosporus
and their effectiveness as a bystander phage therapy. Chapter 3 reviews the phage selection
process for generating a phage cocktail against P. larvae. Also investigated was the detrimental
nature of antibiotics to healthy beehives and an experiment showing the effectiveness of the
phage therapy in treating and preventing AFB. Finally, Chapter 4 is an investigation of the
relationship between phages used in Chapter 3 and the spore form of P. larvae. This study shows
two methods by which phage binding can be quantified as well as provides electron microscopy
images of spore-bound phages.

6

2

CHAPTER 2: “PHAGE-INDUCED TOXIN FROM BREVIBACILLUS
LATEROSPORUS CAN CONTROL AMERICAN FOULBROOD”

The following manuscript “Phage-induced toxin from Brevibacillus laterosporus can
control American foulbrood” was written for and submitted to the Journal of Invertebrate
Pathology, and is currently under review. The article describes the use of B. laterosporus phages
to induce antibacterial toxins to treat American foulbrood.
References for this manuscript are found in chapter 6 and the in text references to figures
or sections are to those within this chapter.
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Abstract
Brevibacillus laterosporus is a bacterium that is often present in healthy and diseased
beehives, with the notable observation of being present in hives infected with the causative agent
of American foulbrood (AFB), Paenibacillus larvae. In current literature, the role of B.
laterosporus in honeybees remains ambiguous due to its ability to cause and prevent disease. In
this work, phages specific for B. laterosporus were found to induce bactericidal toxin production
in B. laterosporus. Results demonstrated that P. larvae is susceptible to the phage-induced toxins
from the two field isolates of B. laterosporus tested. We report the host range of 12 B.
laterosporus phages, three of which were selected for their combined ability to infect 11 of 12 B.
laterosporus strains to create a phage cocktail for the treatment of AFB. Experiments were
designed to show 1) how long phages persist in bee larvae 2) their safety to bee colonies over
time and 3) the efficacy of B. laterosporus phages in treating AFB. Phage presence in bee larvae
after treatment rose to 60.8±3.6% and dropped to 0±0.8% after 72 hours. Healthy hives treated
with B. laterosporus phages experienced no difference in brood generation when compared to
control hives over eight weeks. Twelve AFB infected hives were treated with the phage cocktail
and nine of them recovered, demonstrating a recovery rate of 75%. Despite the success rate of
clearing the active infection, all hives eventually manifested AFB again and symptoms were
controlled with reapplication of the B. laterosporus phage cocktail. These results indicate that
this treatment approach can kill vegetative bacteria but not spores. We posit that the
effectiveness of this treatment is due to the production of the bactericidal toxin of B. laterosporus
when infected with phages. Bystander phage therapy may provide a new avenue for antibacterial
production and treatment of diseases.

9

2.1

Introduction
Brevibacillus laterosporus is a gram-positive, spore-forming bacterium that can be found

in myriad locations including the gut of honeybees (49,60-63). While typically found at low
levels in healthy honeybees, the population of B. laterosporus often increases as a secondary
infection when a hive is infected with Paenibacillus larvae or Melissococcus plutonius, the
causative agents of American foulbrood and European foulbrood respectively (64). American
foulbrood (AFB) is the most devastating bacterial infection in honeybees, killing honeybee
larvae and spreading easily from hive to hive within an apiary (8,65,66). In the wake of antibiotic
resistance in P. larvae, novel methods for controlling AFB outbreaks are needed.
Strains of B. laterosporus produce potent toxins that can kill a wide range of organisms
(49,51,67). B. laterosporus has been used as a biocontrol agent for decreasing the populations of
unwanted bacteria and this method yielded modest results in attempts to control American
foulbrood (68,69). While typically a symbiont of honeybees (52), B. laterosporus can produce
toxins with insecticidal properties and certain strains of the bacterium are implicated in causing
minor disease in honeybee hives after a primary infection (54,56,57,70). The role of B.
laterosporus as either a beneficial symbiont or as an opportunistic infector is yet to be fully
understood.
Prior to this study, phages that specifically infect B. laterosporus were isolated from
beehives and the genomes of most have been studied and published (30,71-73). In this study,
isolated phages were tested against strains of B. laterosporus to determine the most effective
combination of phages to be included in a final cocktail. During isolation and experimentation,
we discovered that when B. laterosporus was treated with phages, the bacteria began to produce

10

toxins that kill P. larvae. These findings led us to believe that B. laterosporus phages could be
used as a biocontrol for AFB by inducing toxin production and killing P. larvae.
The studies presented here show: 1) the host range of identified phages, 2) the phages’
presence and persistence in the larval gut after treatment, 3) the phages’ ability to induce toxin
production compared to other forms of induction, 4) the phages’ safety to healthy honeybee
hives over time, and 5) the phages’ ability to control an active AFB infection. We propose a new
approach called “bystander phage therapy” as a method for treating pathogenic bacteria.
2.2

Materials and Methods
2.2.1

Gathering B. laterosporus field isolates

Samples of honey and hive material were gathered from local apiaries and used to isolate
bacteria. Samples were processed as described previously intended for P. larvae isolation (71,74)
and isolated bacterial colonies were identified as P. larvae or B. laterosporus by PCR.
Specifically, bacteria were initially streaked on PLA agar (75) and incubated at 37°C. Catalase
negative (76) and Gram positive colonies were streaked on LB agar (Becton, Dickinson and
Company, Sparks, MD), gathered, archived in 20% glycerol, and stored at -80°C. Bacteria were
confirmed as B. laterosporus by PCR amplification of the B. laterosporus rpoB gene, see Table
2-1. Samples were also PCR tested with primers specific for P. larvae rpoB and ftsA to confirm
the presence of P. larvae. Prior to PCR, bacterial samples were streaked out to single colonies.
Template DNA for PCR was extracted by adding part of a colony to 50 µL of ddH2O in a PCR
tube and incubating it at 100°C for 10 minutes. The total PCR reaction volume was 25 µL
composed of 22 µL standard PCR reagents (New England Biolabs, Ipswich, MA) plus 3 µL of
template DNA. After 30 cycles, PCR products were run in an agarose gel to confirm

11

Table 2-1. Primer list.
Primers used for amplification and sequencing of rpoB, ftsA, and 16S rRNA genes of B.
laterosporus and P. larvae. Results were used to positively identify bacterial isolates from
beehives.
Primer
27F
907R
BLrpoB-F
BLrpoB-R
KAT1
KAT2
PLrpoB-F
PLrpoB-R
PLftsA-F
PLftsA-R
ERIC1R
ERIC2

Sequence
5'-AGAGTTTGATCMTGGCTCAG-3'
5'-CCGTCAATTCMTTTRAGTTT-3'
5'-GCAGGTAAACTGGTCCAGAGCG-3'
5'-CACCTGTTGATTTATCAATCAGCG3'
5'-ACAAACACTGGACCCGATCTAC-3'
5'-CCGCCTTCTTCATATCTCCC-3'
5'-ATAACGCGAGACATTCCTAA-3'
5'-GAACGGCATATCTTCTTCAG-3'
5'-AAATCGGTGAGGAAGACATT-3'
5'-TGCCAATACGGTTTACTTTA-3'
5′-ATGTAAGCTCCTGGGGATTCAC-3′
5′-AAGTAAGTGACTGGGGTGAGCG-3′

Direction
Forward
Reverse
Forward
Reverse

Purpose
16S rRNA universal
primer

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

P. larvae ERIC-1 or
ERIC-2
Amplifies P. larvae
rpoB
Amplifies P. larvae
ftsA
Generates multiple
amplicons to
fingerprint the
bacteria tested

Reference
(77)

B. laterosporus rpoB
(78)
(79)
(79)
(80)

amplification. Amplicons from the reactions were sequenced using BigDye (Life Technologies,
Carlsbad, CA). MEGA6 was used to match sequence results with bacterial genomes.
2.2.2

Isolating phages specific for B. laterosporus

B. laterosporus phages were isolated from bee debris collected near beehives. Bee debris
was crushed and added to a flask containing LB broth and a field isolate of B. laterosporus. The
bee debris and bacteria were incubated overnight at 37°C. The mixture was spun in a centrifuge
and the supernatant was passed through a 0.22 μm filter (VWR, Radnor, PA). Approximately 50
µL of the supernatant were incubated at room temperature with 500 µL of B. laterosporus
bacteria for 30-60 minutes, mixed with LB top agar, plated on LB agar, and incubated at 37°C
overnight. Plaques that appeared were isolated and re-plated a minimum of three times to purify
individual phage isolates.
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2.2.3

Host range and phage presence testing for isolated phages

B. laterosporus bacterial strains were tested for phage susceptibility using a plaque
formation assay and a spot test assay. For the plaque formation assay, phage lysate was
incubated at room temperature with 500 µL of an overnight culture of bacteria for 30 minutes,
plated in 0.8% LB top agar, and incubated overnight at 37°C. For the spot test assay, 500 µL of
an overnight culture of bacteria was plated in 0.8% top agar. After the top agar gelled, 3 µL of
phage lysate was placed on the top agar. The plates were incubated agar side facing up overnight
at 37°C.
Phage detection in bee larvae was performed by taking one hundred larval samples at
each time point and homogenizing them in 500 µL of LB broth in a 1.7 ml microcentrifuge tube
for approximately one minute. Three µL of the larval homogenate was spotted and incubated on
plates B. laterosporus strains BL2 and BL6 were plated in top agar as described above.
2.2.4

Electron microscopy

Phages were prepared for electron microscopy by incubating copper grids with 50 µL of
high-titer lysate for 90 seconds, wicking away moisture, incubating with 50 µL of 2%
phosphotungstic acid (pH = 7) for 90 seconds, wicking away moisture, and then allowing the
grids to air dry prior to imaging. Electron micrographs were taken on a Helios DualBeam
microscope at the BYU Microscopy Center, and images were measured using ImageJ (81).
2.2.5

Creation of bacterial lysate to test for toxin B. laterosporus and phage cocktail
treatments

Field isolates of B. laterosporus, BL-2 and BL-6, were reconstituted from freezer stock
by plating onto Porcine Brain Heart Infusion (PBHI) (Acumedia, Lansing, MI) plates and
incubating at 37o C for 48 hours. The resulting colonies were streaked to pure culture and
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incubated at 37o C overnight. Fawkes and Emery/Abouo were brought out from freezer stock by
streaking onto PBHI plates with a lawn of B. laterosporus in agar incubated at 37o C overnight.
Picked plaques were grown in liquid culture with overnight growths of B. laterosporus to
generate a high titer lysate. The lysates were centrifuged at 12,000 x g for 30 minutes to pellet
bacterial debris and then passed through a syringe a 0.45 µm filter (VWR, Radnor, PA). The
controls had no phage added and were processed the same to collect a mock lysate.
Overnight cultures of B. laterosporus BL-2/BL-6, P. larvae ATCC 9545, Agrobacterium
tumefaciens field isolate, Sinorhizobium meliloti field isolate, and E. coli B079 were plated using
top agar onto plates of their respective media. Spot assays were conducted on bacterial lawns
using three µL of lysate and incubating overnight. A. tumefaciens and S. meliloti samples were
incubated at 30 o C and all other cultures were incubated at 37 o C.
Phages in the cocktail were generated as described above and then precipitated with
polyethylene glycol (PEG) (Spectrum, New Brunswick, NJ) and centrifuged at 10,000 x g for 15
minutes at 4 o C to obtain a pure phage stock devoid of toxin. The cocktail was applied to the
hives using a spray comprised of phage lysate diluted in a 1:1 sugar/water solution. Control hives
received 340 mL of sugar water, while the phage treated hives received 320 mL of sugar water
with 50 ml of phages containing a total of 108 pfu mixed into the sugar water.
2.2.6

Phage Beehive parameters

In studies beginning with healthy hives, each had a viable laying queen, approximately
40,000 or more adult worker bees, uncapped brood, and no visible signs of American foulbrood.
Sick hives treated in sections 3.5 and 3.6 were identified by a local beekeeper and experimental
treatment was approved through the Utah Department of Food and Agriculture.
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Population growth was determined in each of the hives based on the amount of racks the
bees occupied. A rack was considered full when the space between the racks was fully crowded.
In section 3.4 the phage treatment started once all 12 of the hives achieved at least four fully
occupied racks.
2.2.7

Statistics

The BYU statistical center analyzed the collected data to generate p-values, standard
deviation, and standard error to determine statistical significance using the ANOVA algorithim.
Statistical analysis included repeated measures, mixed procedure, two-tailed analysis using the
Fisher’s exact test for 2x2 contingency tables with α = 0.05.
2.3

Results
2.3.1

Phage characteristics and host range

The genome sequences for all of the phages used in these studies, except for Lauren and
Fawkes, were previously sequenced and analyzed (30,71). Genbank accession numbers for the
phage genomes are as follows: Jimmer1 - KC595515, Jimmer2 - KC595514, Emery KC595516, Abouo - KC595517, Davies - KC595518, Osiris - KT151956, Powder - KT151958,
SecTim467 - KT151957, Sundance - KT151959, Jenst - KT151955.
Electron microscopy images of Jimmer1, Jimmer2, Emery, Abouo, Davies, Osiris, and
Powder were previously published (30,71). Figure 2.1a and b include electron microscopy
images of the two previously unpublished images of phages used in this study, Lauren and
Fawkes, respectively. Figure 2.1c is an image of Fawkes attached to the side of the BL2 B.
laterosporus field isolate.
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Figure 2.1. Brevibacillus laterosporus phages Lauren and Fawkes.
(A) Single Lauren phage particle SEM image. (B) Single Fawkes phage particle SEM image. (C)
Fawkes phage particles attached to BL2 bacterium SEM image, arrows point to attached phage
particles. Images of the other phages mentioned were previously published by (71) and (30).
Upon isolation, B. laterosporus phages were challenged for their ability to infect three
field isolates of B. laterosporus as well as nine type-strains of B. laterosporus from the Bacillus
Genetic Stock Center (BGSC) by both spot tests and plaque formation assays. Table 2-2
indicates bacterial susceptibility to B. laterosporus phage infection using P. larvae bacteria as a
negative control. Emery/Abouo had the largest host range against archived B. laterosporus
strains, showing infectivity against eight of the 12 strains. Fawkes showed infectivity against
seven strains of which three were not covered by Emery/Abouo. None of the tested B.
laterosporus phages were capable of forming plaques on lawns of 40A4. Furthermore, no
plaques formed on P. larvae ATCC 9545, a highly phage susceptible strain, indicating that the
isolated phages are specific to B. laterosporus and do not have the ability to cross-infect into P.
larvae.
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Table 2-2. Host range of B. laterosporus phages.
Twelve B. laterosporus strains and one P. larvae strain were challenged with 12 B. laterosporus phages.
The number of plus signs indicate the level of clearing. A minus sign indicates that no plaque formation
occurred. BL2-BL14 are our field isolates of B. laterosporus, 40A1-40A10 are type strains of B.
laterosporus from BGSC, and PL ATCC is the type strain of P. larvae.
BL2

BL6

BL14

40A1

40A2

40A3

40A4

40A5

40A6

40A8

40A9

40A10

Jimmer1

++++

-

++++

+

-

-

-

-

-

-

-

-

PL
ATCC
-

Jimmer2

++++

-

++++

+

-

-

-

-

-

-

-

-

-

Osiris

++++

-

++

++

+

+

-

+

++

-

++

+

-

Fawkes

++++

-

++

+++

+

-

-

-

+

-

++++

++

-

Lauren

++++

-

++++

+

-

-

-

-

+

-

+

+

-

Powder/Sundance

+++

-

+++

+++

-

+

-

-

-

-

+++

-

-

SecTim467

+++

++

+++

++

+

-

-

-

-

-

+++

-

-

Jenst

-

++++

-

+

-

-

-

-

+

-

+++

-

-

Davies

-

++++

-

++++

++

+

-

+++

+++

+++

-

-

-

Emery/Abouo

-

++++

-

++++

++++

+

-

+++

+++

++

+++

-

-

2.3.2

Phage persistence in the larval honeybee

This study aimed to determine whether phages would reach the larval gut and how long
the phages would persist in a larval gut. Five hives were previously established in a single apiary
and each hives’ brood racks (with the worker bees covering the brood) were sprayed with B.
laterosporus phage lysate suspended in sugar water. One hundred larval specimens were
collected from each hive at spaced time points and were tested for the presence of viable phages,
see Figure 2.2.
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Figure 2.2. Average presence of phages in larvae after treatment.
The time 0 sampling was taken just prior to initial treatment to serve as a baseline. Bees and racks
were sprayed with phages and larvae were plucked from the racks at each time point and tested for
the presence of phages.
The first samples were collected at time 0 immediately prior to treatment with the phage
cocktail to establish a baseline for the presence of naturally occurring phages in honeybee larvae.
Phage persistence studies showed that phage presence in bee larvae was 1.5±0.8% before
treatment and rose to 58.8±3.2% 15 minutes after treatment, 60.8±3.6% after three hours,
52.2±1.8% after 24 hours, 44.9±1.8% after 48 hours, and 0±0.8% after 72 hours. Phages were
found in larvae within 15 minutes of the treatment and peaked at three hours where 60.8±3.6% of
larvae contained detectible, viable phages as determined by spot test. Phage presence in bee
larvae remained well above the normal untreated control for two days after the treatment was
administered. After three days, the phage presence returned to the normal nominal levels.
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2.3.3

Phage infection induces B. laterosporus to produce antimicrobial toxins

During culture of B. laterosporus phages, we observed that bacterial lawns exhibited
clearing from phage plaques as well as a diffusion of some type of toxin in the vicinity of a
plaque. An experiment was designed to characterize the effects of B. laterosporus phage on the
production/release of toxins from B. laterosporus. Strains BL-2 and BL-6 were infected with the
phages Fawkes and Emery/Abouo respectively in duplicate. The resulting lysates were filtered
and three µL spotted onto lawns of different bacteria. Toxin was qualified by the creation of a
zone of clearing in the bacteria on the plate indicating cell die off distinguished between plaques
from phages by observing the shape and size of the clearing (Figure 2.3, Table 2-3). Lysates
from Fawkes and Emery/Abouo both contained toxins that were lethal to BL-2, BL-6, P. larvae
ATCC 9545, and E. coli B079. Neither lysate type was effective against Agrobacterium

Figure 2.3. B. laterosporus toxin spot tests.
Drops of B. laterosporus phage lysate were placed and incubated for 24 hours onto (A) a lawn of A.
tumefaciens that did not respond to the toxin or generate plaque clearings (B) a lawn of P. larvae that
exhibited toxin death, and (C) a lawn of B. laterosporus strain BL2 that showed toxin death as well as
phage infection plaque formation. Brackets indicate toxin clearing, arrow indicates phage plaque
formation.
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tumefaciens or Sinorhizobium meliloti. These data indicate the sensitivity of P. larvae to the
toxin generated by B. laterosporus, and that the toxin is not effective against other bacteria.
Control samples recreated various stages of the phage life cycle to verify phage-induced
toxin production as opposed to toxin release from other mechanisms. Supernatant from UVkilled bacteria was spotted onto lawns of bacteria to identify if bacterial death alone induces
toxin production. The supernatant from mechanically-lysed bacteria was also tested to determine
whether phage lysis releases toxins present in the bacterial cytoplasm. Supernatant from
untreated vegetative B. laterosporus was also tested to identify whether unprovoked bacteria
releases toxin. None of the control sample supernatants formed a zone of clearing in bacterial
lawns, indicating that these mechanisms did not result in toxin production or release as seen in
Table 2-3. Bacterial susceptibility to B. laterosporus toxin.
P. larvae, E. coli, A. tumefaciens, S. Meliloti, and two strains of B. laterosporus were
challenged with the supernatant from two phage lysates and the supernatant of live, dead, and
mechanically lysed B. laterosporus. Toxin-induced death is indicated by plus signs. A minus
sign indicates no discernable toxin clearing on the bacterial lawn.
B.
Laterosporus
(BL-2)

B. laterosporus
(BL-6)

P. larvae

E. coli

A.
tumefaciens

S.
Meliloti

Emery/Abouo Phage
lysate (BL-6)

+++

++*

++++

+

–

–

Fawkes Phage lysate
(BL-2)

++*

+++

++++

+

–

–

Supernatant of live
B. Laterosporus

–

–

–

–

–

–

Supernatant of UV
killed B.
Laterosporus

–

–

–

–

–

–

Supernatant of
mechanically lysed
B. Laterosporus

–

–

–

–

–

–

*Phage plaques were discernable on the bacterial lawns as well as death from toxin
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Table 2-3.The lack of toxin-induction via UV killing and mechanical lysis indicates that the
bactericidal toxin produced by B. laterosporus is not a result of bacterial death or lysis.
Phage-induced toxin production may be the result of expression of toxin genes encoded
by the bacteria since no known toxin genes reside in the sequenced phage genomes while several
toxins have been identified in B. laterosporus (49,67). If the phages carry the toxin gene, then the
toxin sequence must be one of the genes of unknown function in these phages. The fact that more
than one very-genetically-different B. laterosporus phages can induce the bacteria to make an
identically acting toxin indicate that the phages do not carry the toxin genes. Table 2-3 and (71)
may further suggest that the toxin arises from the bacterial genome instead of the phage genome.
2.3.4

Phage-induced B. laterosporus toxin shows inert characteristics against honeybees

This study aimed to determine whether phage treatment for B. laterosporus would be
problematic for honeybees. Since B. laterosporus has been suggested to be a commensal to
honeybees, this study was conducted to observe if side effects of phage-induced toxin or phage
killing of B. laterosporus in the bee gut would decrease the overall health of the hives. Twelve
hives, six in a test group and six in a mock-treated group, were installed into new boxes with new
frames in spring. New queens and approximately 2.5 pounds of honeybees were installed into
each box and weekly inspections were made to follow the bees’ progress by observing the
amount of bees in the spaces between racks. Hives were allowed to become established for nine
weeks before receiving phage or mock treatments. Populations in all treated and untreated hives
stayed below four full racks through early-summer. In mid-summer, the bees began to expand to
fill the fourth rack, at which point the phage treatment commenced.
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All 12 hives were treated three times at weeks nine and eleven, with three days between
treatments for each regiment. Our data show that all hives expanded at approximately the same
rate during the study, see Figure 2.4. There was no statistical difference between the expansion
of the bee populations in mock-treated controls versus the phage-treated group. The data were
evaluated statistically using the repeated measures, mixed procedure, two-tailed analysis of the
number of bee-filled spaces in the treated and control hives over the 17-week period using an
alpha level α=0.05 (P-value of 0.1104). These data indicate that toxin in the phage lysate
treatment was sufficiently low or not active on honeybees. Further, it shows that the hives were
either lacking B. laterosporus and thus this bacterium is not essential for honeybee health, and/or
that any toxin or killing from phage infection of B. laterosporus does not adversely affect

Figure 2.4. Colony expansion after phage treatment in beehives.
New packets of bees with a fertilized queen were allowed to establish in new hives. Arrows indicate when
phage treatments were administered to the bees and results demonstrate that healthy hives treated with B.
laterosporus phage cocktail exhibited no difference in colony expansion when compared to healthy
control hives. Bee spaces indicate honeybee population within the hive.
*Data were not collected for week 13.
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honeybee expansion.
2.3.5

B. laterosporus phages can effectively treat an active AFB infection.

The objective of this experiment was to determine the effectiveness B. laterosporus
phages in curing honeybee hives of American foulbrood caused by P. larvae. Forty hives of
honeybees (Apis mellifera) were previously established in one apiary. Twelve of the 40 colonies
presented with American foulbrood, the remaining 28 colonies were relocated to prevent the
spread of the disease to the remaining healthy hives. All 12 sick hives were treated three times
(each treatment was given three days apart) by spraying each rack on both sides with B.
laterosporus phages in sugar water. The remaining 28 hives appeared healthy and were treated
with antibiotics by the beekeeper. Treatment of the beehives occurred immediately before the
onset of winter.
All 40 hives were inspected two weeks after the first treatment. Nine of the 12 infected
hives treated with B. laterosporus phages recovered and showed no signs of AFB upon
inspection at week two, which indicates a 75% cure rate (see Table 2-4). Two of the 28
originally uninfected hives were diagnosed with AFB despite their initial healthy appearance at
the beginning of this study. The two hives had received antibiotic treatments along with the other
Table 2-4. Survival rate of hives after treatment in fall and after winter.
Infected hives received phage cocktail treatments and uninfected hives were prophylactically
treated with antibiotics. Survival rates of the hives were evaluated after two and 16 weeks.
Total
hives

AFB-free
post-treatment

Hive Survival
over winter

Uninfected hives

28

92.85%*

78.1%†

AFB infected hives

12

75%

62.5%

*Two hives of the 28 uninfected became infected when they were removed from the initial 12 infected
†Results excluding the two hives that became infected with AFB
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26 healthy hives; however, both hives collapsed with severe signs of AFB which suggests that
the infecting strain of P. larvae was antibiotic resistant. Dead-out hives were burned. No further
problems were reported with the other 26 hives. Dead larval samples were taken from the hives
before the first phage treatment and healthy larvae at two weeks post-phage treatment (healthy
larvae were taken post-treatment because no dead larvae were observed). The larval samples
were analyzed by PCR for the presence of bacteria. Results of PCR confirmed the presence of P.
larvae and B. laterosporus DNA at pre-treatment, and only P. larvae DNA with no amplification
of B. laterosporus DNA at post-treatment. The nine hives that recovered from AFB were
followed through winter. In spring, of the nine recovered hives, five survived, four died. No
signs of AFB were found in the four dead hives; three of the hives appeared to have frozen to
death, and one hive was destroyed by vandals.
2.3.6

B. laterosporus phages do not prevent reinfection by latent P. larvae spores.

The five recovered, surviving hives were followed for nine months to investigate the
effectiveness of the B. laterosporus phage cocktail in the inactivation of latent P. larvae spores,
see Table 2-5. Two weeks after phage treatment as well as in the following spring, 16 weeks
Table 2-5. Health of five hives after an AFB outbreak, B. laterosporus phage treatment, and
overwintering.
The surviving hives after B. laterosporus phage treatment were monitored for 28 weeks
after initial treatment. When hives were seen to relapse, all hives were retreated with the
phage cocktail.
Week 16

Week 18*

Week 20

Week 22*

Week 24

Week 26*

Week 28

Healthy

5

4

5

3

5

0

5

AFB +

0

1

0

2

0

5

0

*Weeks when phage cocktail was administered
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after the first treatment, all five hives had no signs of AFB infection. At 18 weeks, one of the five
surviving hives experienced an AFB infection and that hive recovered after another treatment of
B. laterosporus phages. At each time of recurrence, all 5 hives in the apiary were symptoms
preemptively treated with the phage cocktail. At week 22, the first hive and a second hive
experienced AFB symptoms, which were again treatable with B. laterosporus, signs of AFB
disappearing within a week of the treatment. By week 26, all five hives presented with AFB
symptoms and were treated with the phage cocktail, which again cleared all of the hives of AFB
symptoms with 2 weeks. All hives were destroyed mid-summer due to the reoccurring infections.
These data indicate that B. laterosporus phage treatment could kill active P. larvae infections,
but could not kill P. larvae spores nor prevent future infection.
2.4

Discussion
The phage cocktail used in these studies was formulated to specifically infect a wide

range of B. laterosporus field isolate strains. As seen in (82) and (83), phage cocktails designed
in this manner (with phages in the cocktail selected according to the ability to kill as many field
strains as possible) are effective at reducing the amount of their target bacteria. Here, we
observed that the phages selected for a cocktail using laboratory-generated data of phage efficacy
was predictive of the efficacy of phages in field tests, as observed by the reduction in the amount
of B. laterosporus DNA present in hives. Furthermore, we studied the toxin-inducing capabilities
in the laboratory to observe whether or not the toxin could be effective at reducing P. larvae
bacteria, and then applied our results to safety and efficacy studies in the field. Using B.
laterosporus phages as a biocontrol comes with some inherent risk. We were concerned to know
whether, by inducing toxin synthesis and lysing B. laterosporus, the phage cocktail could release
toxins with insecticidal properties or other adverse effects in honeybees. No such deleterious
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effects were seen in our studies. Firstly, we observed rapid loss of detectable phages in healthy
larvae (Figure 2.2), which indicates that a phage treatment has a relatively short exposure time to
the bees. Secondly, we observed no short-term or long-term harm to healthy honeybees treated
with multiple doses of phages (Figure 2.2, Table 2-4, and Table 2-5). These studies add to the
expanding literature that indicates that phage cocktails are a safe alternative to traditional
antibiotic use (36,37,84-88).
This study indicates that B. laterosporus is not a necessary symbiont for honeybee health,
which conclusion is contrary to the postulations of several other researchers (51,69) but supports
reports by others (49). The current field of research surrounding B. laterosporus is tempestuous
as to its merits and disadvantages. However, the research conducted in this article is uniquely
equipped to demonstrate the effects of beehives with and without B. laterosporus in vivo and the
results indicate that there are no significant differences between hives with or without the
bacteria. This study also demonstrates advantages to having the bacteria naturally present and
using phages to induce toxins to kill pathogenic bacteria.
One aim of our studies was to determine whether a phage cocktail designed for a coinfecting or commensal bacteria (B. laterosporus), could reduce the presence of a pathogenic
bacteria (P. larvae), during a disease state (AFB infection). Figure 2.5 depicts this new
“bystander phage therapy” as a phage treatment approach compared to the current dogma of
phage therapy. Such situations may be more common than just this B. laterosporus/P. larvae
system because a co-existing, non-pathogenic bacteria may evolve to secrete toxin in order to
out-compete a pathogenic bacteria. The “bystander” bacteria may be poised to produce toxin
under stress as we were able to do using phage infection. It is important to note that none of our
B. laterosporus phages could infect P. larvae. Therefore, any activity of a cocktail of B.
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laterosporus phages against AFB must be either from toxin release to induce bystander killing of
AFB or that B. laterosporus is responsible for AFB. We do not believe the latter is true. It was
already known that B. laterosporus can produce antimicrobial toxins (49,67) and results from our
laboratory experimentation in section 3.4, and Table 2-3, demonstrate that these compounds are
effective against P. larvae as well as other unrelated bacteria. As seen in section 3.5 and Table 24, the phage cocktail can clear an active AFB infection but is not curative as observed by the
recurrent infections presented in Table 2-5, section 3.6. We hypothesize that the toxins released
by the phage when infecting B. laterosporus are effective against the vegetative bacteria that
infect the larval brood, but that the toxins are not strong enough to eradicate P. larvae spores.
The B. laterosporus phage treatment used in these studies demonstrated a 75% success
rate in recovering actively-infected beehives from AFB. After B. laterosporus phage treatment,
the recovered hives were sufficiently healthy to overwinter, albeit at a slightly lower rate than the
national overwinter average. This particular AFB outbreak was sufficiently virulent to cause
complete collapse of a beehive, as observed in the two hives that were misidentified in the
healthy control group that must have been infected at the start of the study. The virulence of the
bacteria is evident by the loss of these two colonies within two weeks of the study start time,
despite antibiotic treatment, and during the same time period that the diseased colonies
completely recovered after B. laterosporus phage treatments. AFB-diseased beehives treated
with B. laterosporus phages retain bacterial spores from the infection and required ongoing
maintenance to prevent recurrent AFB the following spring and summer.
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These results indicate that the AFB infection was caused by a P. larvae infection as
would be expected, and further that B. laterosporus phage treatment can clear a P. larvae
infection despite it not infecting P. larvae. The recurrent infections indicated that P. larvae
spores remained in the hives after the B. laterosporus treatment in a similar manner as occurs
after antibiotic treatments of AFB-infected hives.
Bystander phage therapy has an advantage over typical phage therapy because the range
of targets affected by the toxin can be much greater than traditional phage therapy that has
limited host range. For instance, bystander phage therapy does not rely on the phage killing all of
its targets. Rather, the phages only need to infect and induce enough bacterial toxin to kill the
pathogen (Figure 2.5). By this method, a hive could be infected with several strains of P. larvae
that could include phage resistant P. larvae because of the limited host range of the individual
phages, but the bacteria could still be killed by the phage-induced B. laterosporus toxin. This
bystander effect could occur regardless of whether or not all strains of the non-pathogenic

Figure 2.5. Mechanism of pathogen killing using phages for traditional phage therapy versus bystander
phage therapy.
Phages against a pathogenic bacterium bind and lyse some bacterial strains, but may leave others
unscathed. Phages against a bystander induce the bystander to make a toxin that kills all versions of the
pathogenic bacteria and possibly other strains of itself that were not infected by phages.
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bacteria (B. laterosporus) are killed. An option not to kill all target bacterium is useful and
desirable for a phage therapy approach because it means that the cocktail for bystander phage
treatment would not need to include phages to kill every possible bacterial strain of its target.
This simplifies the cocktail itself, and increases the chances of the treatment being functional
since it is not dependent on killing all bystanders, but simply on activating the bystander to kill
the pathogen.
Due to the nature of the antimicrobial effects of the toxin produced by B. laterosporus,
bystander phage therapy could function as treatment against other bacterial infections in beehives
such as M. plutonius, the causative agent of European Foulbrood. If the phage-induced toxin is
lethal to other pathogens such as M. plutonius, then it would be an attractive alternative to
standard phage therapies because of its ability to treat various diseases. This approach is
especially helpful in the case of misdiagnoses, since B. laterosporus could be present regardless
of the pathogen causing symptoms in the hive. Culture of certain bacterial pathogens, such as the
anaerobic bacterium M. plutonius, can be difficult to accomplish in the lab and therefore make it
difficult to isolate phages for traditional phage therapy treatment. By inducing a bystander
bacterium to produce a toxin, phages can remain a treatment option even for difficult-to-culture
bacteria.
2.5

Conclusions
Phage therapies are an attractive alternative to traditional antibiotic use in the face of

antibiotic resistance in pathogens. This study presents bystander phage therapy as a new
alternative approach for phage therapy. The phages used in this study did not target the pathogen
causing the disease that it treated, but rather targeted a known co-infecting bacterium and
induced the co-infecting bacteria to produce toxins to which the pathogen is sensitive.
29

The properties of phage-induced toxins produced by B. laterosporus can be characterized
to establish the extent of their host range. This research demonstrated that phages can induce B.
laterosporus to produce bactericidal toxins and demonstrated how phages that kill bystander
bacteria can also result in killing of off-target, pathogenic bacteria. This approach could be useful
as a single treatment for different diseases caused by different pathogens with overlapping
symptoms provided that the phage-induced toxin can kill both pathogens, and that the loss of the
toxin-producing bystander bacteria is not vital to the organism. In this case, B. laterosporus is
not a vital commensal and treatment of healthy bees with B. laterosporus phages did not result in
any detectable health consequences in the bees. Use of B. laterosporus phages rescued a
significant number of sick hives from succumbing to an antibiotic-resistant form of AFB. The
use of bystander phage therapy is an exciting and new avenue of study that merits further
investigation in the field of phage research.
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3

CHAPTER 3: “BACTERIOPHAGES AS AN ALTERNATIVE TO CONVENTIONAL
ANTIBIOTIC USE FOR THE PREVENTION OR TREATMENT OF PAENIBACILLUS
LARVAE IN HONEYBEE HIVES"
The following manuscript “Bacteriophages as an Alternative to Conventional Antibiotic

use for the Prevention or Treatment of Paenibacillus larvae in Honeybee Hives" was written for
and submitted to the Journal of Invertebrate Pathology, and was published November 2017. The
article describes the creation of a phage cocktail to treat and protect at risk hives from American
foulbrood.
References for this manuscript are found in chapter 6 and the in text references to figures
or sections are to those within this chapter.
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Abstract
American foulbrood (AFB) is an infectious disease caused by the bacteria, Paenibacillus
larvae. P. larvae phages were isolated and tested to determine each phages’ host range amongst
59 field isolate strains of P. larvae. Three phages were selected to create a phage cocktail for the
treatment of AFB infections according to the combined phages’ ability to lyse all tested strains of
bacteria. Studies were performed to demonstrate the safety and efficacy of the phage cocktail
treatment as a replacement for traditional antibiotics for the prevention of AFB and the treatment
of active infections. Safety verification studies confirmed that the phage cocktail did not
adversely affect the rate of bee death even when administered as an overdose. In a comparative
study of healthy hives, traditional prophylactic antibiotic treatment experienced a 38±0.7%
decrease in overall hive health, which was statistically lower than hive health observed in control
hives. Hives treated with phage cocktail decreased 19±0.8%, which was not statistically different
than control hives, which decreased by 10±1.0%. In a study of beehives at-risk for a natural
infection, 100±0.5% of phage-treated hives were protected from AFB infection, while 80±0.5%
of untreated controls became infected. AFB infected hives began with an average Hitchcock
score of 2.25 out of 4 and 100±0.5% of the hives recovered completely within two weeks of
treatment with phage cocktail. While the n numbers for the latter two studies are small, the
results for both the phage protection rate and the phage cure rate were statistically significant
(α=0.05). These studies demonstrate the powerful potential of using a phage cocktail against
AFB and establish phage therapy as a feasible treatment.
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3.1

Introduction
American foulbrood (AFB) is one of the most widespread and destructive bee brood

diseases. AFB is caused by the spore-forming bacterial pathogen Paenibacillus larvae and is
spread by worker honey bees inadvertently collecting P. larvae spores from the environment or
contaminated hives (65). If worker bees retain spores in their honey stomach, they can infect the
bee larvae (brood) while regurgitating the contents of their honey stomach (including the P.
larvae spores) during larval feeding (16). When infection occurs, the spores germinate and kill
the bee larvae. The bacteria liquefy the larvae, producing a viscous, spore-laden fluid. The
disease spreads rapidly within a hive and can destroy entire hives if the infection is left untreated
(66). Antibiotics, Oxytetracycline and Tylosin Tartrate (Tylan® Soluble™), are commonly used
to prevent and treat AFB infections. However, antibiotic treatments have several disadvantages.
For instance, many wild strains of P. larvae have antibiotic resistance to Oxytetracycline
(24,28,40,43,89,90). In a 2006 study, 58% of field samples were resistant to oxytetracyline (28).
The only alternative to oxytetracycline for treating AFB is Tylosin Tartrate, which has resulted
in Tylosin being the most commonly used conventional antibiotic for the treatment of AFB in the
United States today. Antibiotic residue in honey also poses health risks to children and
developing babies (41). Antibiotic treatments can increase the chances of fungal infection,
nosema, due to disruption of the normal balance of bacteria in the bee gut (20). Furthermore,
recent legislation prevents beekeepers from purchasing antibiotics over the counter, requiring a
veterinarian visit and prescription to receive any antibiotics. Hives must be burned when
antibiotics fail to cure AFB infections to prevent it’s spread to other hives in an apiary.
P. larvae, like all bacterial species, has natural opponents called bacteriophages (phages).
Phages are viruses that only infect and replicate in bacteria and have the potential to overcome
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the disadvantages posed by antibiotics. A single type of bacteria will have many phages that are
specific for that bacterium (91,92). The extreme specificity of phages is observed as their ability
to bind and infect only their target bacterium and leave other cell types, bacterial and eukaryotic,
unharmed. The specific killing activity of phages makes them an ideal replacement for
antibiotics.
In this study, 39 phages were isolated that infect P. larvae. Each phage was tested against
59 bacterial strains of P. larvae and the results indicate a variety of infection capacity of each
phage. Based on the results of phage infectivity and bacterial lysis in-vitro, three phages were
selected for testing in beehives. The selected phages were cultured and concentrated to generate
a phage cocktail treatment. The phage cocktail was then used in live beehives to explore the
phages’ effect on the overall health in beehives compared to traditional antibiotics, and the
phages’ ability to clear and protect against AFB in a naturally occurring outbreak. In the beehive
studies, the phage cocktail appears to be safe for bee consumption, the phages can protect hives
from an impending infection and the phages are capable of quickly curing infected hives.
3.2

Materials and Methods
3.2.1

Bacterial and phage infectivity.

Isolated phages were grown from the bacterial strain P. larvae ATCC 9545. The bacteria
were grown in Porcine Brain Heart Infusion (PBHI) (Acumedia, Lansing, MI) broth overnight in
a shaking incubator at 37 ºC and 120 rpm. Colony forming units (cfu) determination was made
using the equation C=A/E where A is absorbance at 580nm, E is 6.6*10^-9, and C is cfu of P.
larvae/mL. Flasks prepared with ¼x PBHI broth were inoculated with 10^7 cfu/mL of sterile
broth. A well-titered phage lysate is added to the broth such that the final number of pfu of phage
in the flask is 1/3 of the number of cfu of P. larvae. The mixture was allowed to incubate for 1235

18 hours as described above. After incubation, the solution was filtered through a 0.2 µm sterile
syringe filter and the lysate containing phages was stored at 4 ºC.

The titer of the lysate was tested as previously described (71). Briefly, a serial dilution of
the phage lysate is made to the 10^-5 dilution. The dilute phages are added to bacteria grown
overnight in 10 mL incubation tubes and were allowed incubate at room temperature. PBHI top
agar was added to the mixture after 30 minutes and then the entire mixture was plated onto
previously prepared PBHI agar plates (Fisher Scientific, Fair Lawn, NJ). Plaques were counted
12-24 hours later to calculate titer with the equation (plaque number)/(phage dilution)(mL
infected) = pfu/mL.
3.2.2

Control sugar water mixture, phage cocktail treatment, and antibiotic treatment
preparation.

The treatment mixture for trough feeders was comprised of 2:1 volume:volume sugar
water. Sugar water was poured into the feeder trough for the control hives. Phage lysate was
added to 500 ml sugar water, at a 1x recommended treatment consisting of 20mL, titered at
5x108 plaque forming units per ml, and was then poured into the feeding troughs of the hives
receiving treatment. For spray on phage treatment a 1:1 sugar water was used instead of 2:1.
Control hives received 340 mL of sugar water, while the phage treated hives received 320 mL of
sugar water with 50 ml of phages mixed into the sugar water. For antibiotic treatment, 200mg
Tylan® Soluble™ (Elanco™, Greenfield, IN) was mixed in 20 grams of powdered sugar for
each hive and the mixture was dusted onto the top bars of the brood chamber.
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3.2.3

Criteria for healthy hives to be included in studies.

Each of the hives had to meet the following four criteria: a viable laying queen, contain
approximately 40,000 or more adult worker bees, have uncapped brood, and have no visible
signs of American foulbrood. All hives used in the healthy hive studies met these criteria.
3.2.4

Three-brood rack test, Hitchcock scale test, and non-AFB illness tests qualifications.

These tests were to assess the AFB infection level of a hive. Observation of three full
brood racks from a single hive constituted a complete AFB hive inspection. Any hive that had a
brood rack that showed signs of illness were inspected for signs of AFB beyond the 3-brood
racks using the Hitchcock scale of infection. For each indication of AFB, the hives were rated on
a 0-4 scale based on a modification of the method proposed by Hitchcock, 1970 (93). Briefly,
hives are examined and each of the frames rated as follows: 0= no signs of disease, 1= <10 cells
per frame affected, 2= 11-100 cells per frame affected, 3= > 100 cells per frame affected, and 4=
total hive collapse/death. In non-AFB illness tests, a hive was counted as “diseased” if it
developed AFB, chalkbrood, European Foulbrood, or struggled to thrive when a queen stopped
laying well and the hive could not maintain population even if there were no other visible signs
of disease. All hives were inspected using these methods and scores were determined during
inspections.
Statistics used. The BYU statistical center was used to generate p-values, standard
deviation, and standard error to show the statistical significance of the data collected using the
ANOVA algorithim. Statistical analysis included repeated measures, mixed procedure, twotailed statistical analysis using the Fisher’s exact test for 2x2 contingency tables with α = 0.05.
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3.3

Results
3.3.1

Phage infectivity of bacterial strains in culture can be used to select phages for a
treatment cocktail.

Our objective was to identify phages for our treatment study that could infect and kill a
wide range of P. larvae strains. A total of 39 P. larvae-specific phages were tested for their
infectivity against 59 field strains of P. larvae and the results of lytic testing are summarized in
Figure 3.1. In Figure 3.1, bacterial field isolates are listed in each column in the order in which
the bacterial strain was isolated and numbered. Phages are listed in rows down the table in the
order of the number of strains that the phage lysed. For instance, Phage 1 comprises the top row
in the table because of its ability to lyse all but four bacterial strains and phage 39 could only
lyse one strain of the 39 strains of bacteria. Phage 40 was a negative control using a phage that is
not capable of infecting P. larvae.
The formulation of the phage cocktail arose from the results of the host range test in
Figure 3.1. Three phages were selected (phages 1, 5 and 9) for subsequent work in beehives
based on the combined ability of these phages to lyse all field isolate strains. Phage 1 lysed all
field isolates of P. larvae except for PL314, PL323, PL328, and PL334a. Phage 5 lysed several
strains including PL314, PL323, and PL334a. Neither phage 1 nor phage 5 could lyse strain
PL328. Phage 9 lysed fewer strains but did lyse strain PL328. The combination of phages 1,5
and 9 into the phage cocktail meant that all the field isolates tested could be lysed by one or more
of the phages when administered to the beehives. To prepare a phage cocktail for testing in hives,
a high titer lysate was prepared for each of the three phages. Prior to combining phages, the
lysates were sterile-filtered to remove any residual bacteria and the lysate was tested for the
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presence of any bacteria. Bacteria-free lysate was titered and then diluted in the cocktail to the
appropriate phage concentration.
Selection of phages in the cocktail was based on the physical (lytic) ability of the phages
rather than their genetic similarity or dissimilarity to one another. All phages used in the phage
cocktail have a lytic lifecycle as represented by their leaving clear plaques when plated with P.
larvae. Although the genetic information is not yet available for the phages used, several phages
that target P. larvae have been classified as part of the family Siphoviridae and display either
prolate or icosahedral heads with long and flexible tails (71,85,94).

Figure 3.1. Phage host range testing results.
Solid black boxes indicate that the phage of that row was able to lyse the bacterial field isolate of that column.
Blank spaces indicate that the phage did not make visible plaques when incubated with that bacterial field
isolate.
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3.3.2

Highly concentrated phages in honeybee feed demonstrate anticipated inert
characteristics.

A total of 24 hives of honeybees (Apis mellifera) were previously established in three
apiaries near one another. The 24 hives were separated into four groups and each group received
one of four treatments: a control solution of sugar water or dilutions of phages at 0.5x (2.5x108
pfu/ml), 1.5x (7.5x108 pfu/ml), and 2.5x (12.5x108 pfu/ml) of the recommended concentrations
administered via feeding troughs. All hives were treated nine times (three times the amount of a
standard preventative treatment) so that all treatment groups received what would be considered
an overdose of the treatment. Dead bees were collected in traps below hives so that bodies
dropped by workers could be counted each week to determine whether an increased

Figure 3.2. Average bee death over time in control and P. larvae phage-overdosed beehives.
Hives were treated with doses of phage cocktail and average number of dead bees were counted over time. No
statistical difference (P-value of 0.639) was observed between any of the test groups versus each other or the
control group.
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concentration of phages could produce any increase in bee death. Hives were inspected eight
times and dead bees were counted. Results of this study are presented in Figure 3.2.
All 24 hives experienced a reduction in bee death over the summer months and remained
AFB negative from June 25 to August 20, indicating overall healthy hives. No statistical
difference was observed in bee deaths between the different phage concentrations and the control
samples (Figure 3.2). The p-value measured for the repeated measures, mixed-procedure, and
two tailed statistical analysis was 0.639 with a 95% confidence level. One hive in the 1.5x group
was observed to be an outlier and exhibited higher death rates than all other hives. The results of
data comparison between groups remained insignificant whether this group was included in the
statistical analysis or not. From these findings, we see that dosing and even overdosing bees with
phages does not adversely influence the death rate of AFB-free hives, as would be anticipated.

Table 3-1. Hives treated with Tylan® and P. larvae phages
Hives at each apiary were assigned to one of three groups to divide the 96 hives equally
between treatments.
Group

Apiary 1

Apiary 2

Total # of Hives Treatment Regimen

Control

16

16

32

Three treatments of 2:1 sugar water
in feeding trough.

Tylan®

16

16

32

Three treatments of Tylan in
powdered sugar in early spring and
in early fall.

32

Three treatments of PL Phages in
2:1 sugar water in late spring and
in early fall in feeding trough*.

PL
Phages

16

16

*Some hives received spring PL phage treatment as a spray of instead of in the trough but
the volume and contents of the treatments were identical for all hives.
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3.3.3

Phages maintain hive health while traditional antibiotics are detrimental to
honeybees.

A total of 96 beehives were previously established in two neighboring apiaries, 48 hives
in each apiary. Each apiary was randomly divided into three equal groups, see Table 3-1. All 96
hives were inspected in spring and fall using a 3-brood rack approach. All hives were healthy at
the beginning of the study and were treated in spring with a normal treatment cycle consisting of
3 doses of sugar water, phages or antibiotics according to what the individual hive was assigned.
Hives were inspected again at the end of summer. None of the 96 hives in this study became
infected with AFB. Three of the 32 control hives became diseased. A hive was counted as
“diseased” if at any time it developed any of the following: chalkbrood, European Foulbrood, the

Figure 3.3. Honeybee health in hives that received prophylactic antibiotics, phages, or mock treatments.
Treatments were administered in healthy hives during spring. Results depict the number of hives remaining
healthy upon inspection at the end of summer with SEM bars indicated for each group. *Statistically
significant at α =0.05.
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queen stopped laying well, or the hive struggled to survive. Results of this study are presented in
Figure 3.3.
Twelve of the Tylosin Tartrate-treated hives became diseased, leaving 62±0.7% of the
antibiotic-treated hives remaining healthy. There is a statistically significant difference with a pvalue of 0.0146 in the antibiotic-treated group in comparison to the control group using a twotailed Fisher’s exact test for 2x2 contingency tables with 95% confidence, indicating that
antibiotic treatment reduces overall hive health. Of the control hives, 90.6±1.0% of the hives
remained healthy, and of the P. larvae phage-treated hives, 81.3±0.8% of the hives remained
healthy. There is no statistical difference between the phage-treated hives and the control hives,
having a p-value of 0.4741 using the same evaluation as stated previously, which indicates a lack
of evidence of any detriment to the bees due to phage treatment.
3.3.4

Phages Protect At-Risk Hives from AFB

A total of eleven beehives were previously established in a single apiary. One hive
became infected with AFB from an unknown (natural) exposure and the other ten hives were still
AFB negative at the beginning of this study. The ten originally healthy hives were divided into
two groups: five were spray-treated with sugar water as a mock treatment and the other five were
spray-treated with the phage cocktail in sugar water. The initially infected hive was also spraytreated with phage cocktail in sugar water (see the next section). All hives were treated three
times in the first 10 days and observations and Hitchcock scores were taken at day zero and
every two weeks for eight weeks, then again at four months. Any hives that became diseased
with AFB during the study were treated with the phage cocktail immediately upon observation of
diseased comb. Results are presented in Figure 3.4.
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Figure 3.4. Phages effectively prevent and clear AFB.
At risk hives were treated with phages and control sugar water three times within 10 days starting at day 0.
At the Week 2 inspection, all of the beehives were healthy (Hitchcock score=0, data not shown). At the
Week 4 inspection, mock-treated hives exhibited signs of AFB and the average±SEM Hitchcock score is
reported here (A). Any infected hives were immediately treated with phages and their Hitchcock scores
before and two weeks after treatments were recorded (B). The Hitchcock infection severity score ranges
from 0-4, with 0=no signs of AFB, and 4=hive death from AFB (see Materials and Methods). *Statistically
significant at α =0.05.
The ten healthy hives were used to determine the phages’ abilities to protect against an
infection when housed near a sick hive. At day zero, all ten hives were healthy and had a
Hitchcock score of 0. At week two, all ten hives were still healthy and had a Hitchcock score of
0. At week four, four of the five mock-treated hives were sick with AFB. One of the four was
already sick beyond recovery (Hitchcock score=4), was abandoned by the queen and had very
few adult bees remaining with severe AFB throughout the brood racks. The other mock-treated
hives had scores of 1, 1, 3, 0. Results of the mock-treated hives indicate that the infection spread
rate was 80±0.5% for this incident of AFB. In contrast, all five phage-treated hives remained
healthy with Hitchcock scores of 0 in all five hives. The average Hitchcock score±SEM for the
Week 4 inspection in the phage-treated and mock-treated groups is presented in Figure 3.4A.
These data indicate that the phage cocktail was 100%±0.5% protective for the at-risk hives. The
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results between groups were statistically significant with a p-value of 0.0016 using a Least
Square Means in a Mixed Procedure analysis.
3.3.5

Phages Clear Hives of P. larvae Infection

In the previous study, the originally infected hive that put the other ten at risk, along with
the three mock-treated hives that were still alive at the week four observation point, received the
phage treatment in an attempt to cure the hives of AFB as immediately as it was observed.
Within two weeks of phage treatment, all four of these hives were AFB-free, each with
Hitchcock scores of 0. At the beginning of the study, the only one of the eleven hives with AFB
had a Hitchcock score of “2.5”, and it recovered fully by week two. Of the five mock-treated
hives, the one hive with a score of 4 at week 4 was burned, and the other three AFB-infected
hives from the group were phage treated and all three fully recovered by week 6. The recovery of
these three hives plus the recovery of the originally sick hive indicate that four of the four P.
larvae-infected beehives recovered, which is a 100%±0.5% recovery rate from this study. The
average±SEM Hitchcock score before and after phage treatment is presented in Figure 3.4B. The
difference between the before and after scores is statistically significant, with a p-value of 0.0022
using the same statistics as the previous study. At week eight, all hives remained free of AFB.
In fall, all ten of the surviving hives in the apiary were healthy and lacked signs of AFB.
Honey was harvested from all ten hives. The hives were inspected again in October, four months
after the infection and just prior to entering winter, and all ten hives remained healthy and lacked
any signs of AFB. These data indicate that the phage cocktail successfully treated the infection
and prevented recurrence.
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3.4

Discussion
The phage cocktail used in this study was the direct result of laboratory host range testing

and showed remarkable practical application in the field. Phages are known to infect multiple
strains of the same or highly related bacteria. For instance, Jacobs-Sera et. al, identified 220
mycobacteriophages with overlapping ability to infect specific strains of M. smegmatis and M.
tuberculosis (32). Mirzaei and Nilsson performed a host range analysis of phages against 72
strains of E. coli in an effort, identical to our approach, to select the best phages for a cocktail
treatment (87). Salmonella phages were also isolated and compared for infectivity of 26 different
strains of bacteria, with the highest host range phage being able to lyse 25 of 26 of the strains,
and the lowest host range phage able to lyse 6 of the 26 strains (95). In our study, the most
effective phage lysed 55 of our 59 strains of P. larvae and the least capable of our phages only
infected one strain.
Only 22 P. larvae bacteriophage genome sequences have yet been published
(85,94,96,97), compared to over 627 bacteriophage genomes of M. smegmatis (98). In this study,
genetic comparisons were not attempted, but rather, each phage was tested for its lytic ability
across the field isolates in order to identify the functionality of these phages to lyse one or more
strains of the bacteria. Using results of the phages vs. bacterial strains study in Figure 3.1, the
phage cocktail was based on the physical ability of the phages to lyse P. larvae strains rather
than their genetic similarity or dissimilarity to one another. Genetic comparisons of phage
genomes, such as the expanding work in M. smegmatis phages, have revealed complexity in
interpretation of phage function to phage genomics. Functional assays, such as lytic tests
spanning a variety of strains, are a valuable method to identify appropriate phages for field
testing.
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The safety of phages to non-target organisms has been well documented (3639,47,85,99). Phages in the cocktail used in this research showed no discernable negative effects
on bee hives as would be expected from the nature of phages. Phage therapy does not alter
normal bee deaths nor their gut microbiota besides that they can infect and kill P. larvae. This
study demonstrates the safety of phages, even when administered in high doses, for prophylactic
use against AFB. These results are not surprising given the specific nature of phages, though
they do add to the consensus of the literature that phages do not typically infect or harm bacteria
for which they are not specific (100-103).
Antibiotics like Terramycin and Tylosin the only currently known antibiotics that have
been effective against AFB; however, these antibiotics are deleterious to the overall health of
hives when used prophylactically, as demonstrated in our study and also reported by others (20).
Furthermore, the tetracycline family of antibiotics, to which Terramycin and Tylosin belong,
causes bone and tooth deformities for fetuses and breast feeding infants (41,89,104). Treatment
during honey-producing months yields honey with measurable amounts of antibiotics and
therefore reduces the safety of honey consumption for those at risk (105). Due to the non-specific
toxicity of antibiotics, both harmful and good gut microbes are killed when they are applied to
the hives. This toxicity decreases the gut diversity of the honeybee which in turn makes them
less healthy (20,43). In our side-by-side trial of phage treatment and Tylosin, the hives that were
prophylactically treated with antibiotics had a decrease in hive health while the phage treated
hives remained healthy in comparison with the control hives.
Antibiotic resistance in AFB has begun to render the treatment of hives with antibiotics
obsolete (40,43). Resistance to phages is more difficult to achieve for the bacteria because the
phages also have slight variations from generation to generation, making it possible for phages to
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keep in step with any mutant strains of P. larvae (32). A concern for the future use and
effectiveness of phage cocktails is the possible existence of a strain of P. larvae that might not be
hit by a phage in the cocktail. However, we believe that the risk of strain specificity is
preferential to the health risks and resistance associated with antibiotics. Furthermore, the use of
a combination of phages in a treatment cocktail improves the likelihood of the phage treatment
being effective against all bacterial strains. Phages are prevalent in the environment and can
typically be readily isolated, which makes phages easier to discover than the production of novel
traditional antibiotic chemical structures that will also eventually become obsolete due to
antibiotic resistance.
We believe that the marked effectiveness of the phage cocktail in the prevention of AFB
infection in our studies can be attributed in part to the combined host range of the phages
included in the cocktail. Similar studies have been performed in situ with larval bees inoculated
with a phage cocktail and then dosed with P. larvae spores. The phage-treated larvae showed the
same survival rate (84%) as control larvae that did not receive phage nor spores; whereas, mocktreated larvae experienced a 45% survival rate (106). Another study showed that prophylactic
phage cocktail dosing was able to increase the chances of larval survival by approximately 59%
(85). The results from our study coincide with the results found by Ghorbani-Nezami et al. and
Yost et al. that phage dosing can successfully be used prophylactically and after infection against
AFB. Our study is the first in vivo phage treatment for AFB and, insofar as the results indicate, it
is highly effective as such.
3.5

Conclusions
Phage cocktails have become increasingly popular as a solution to difficult-to-treat

bacterial infections over recent years (38,83,86,88,99,106-110). Due to the nature of P. larvae
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infections, phages are supremely suited for clearing AFB from infected hives. P. larvae is
introduced to larval bees via nurse bees that feed them. The phage treatment is delivered to the
site of infection in the same way. When nurse bees eat phage-laden sugar water from feeding
troughs, they take the phages to larvae that may have been exposed to P. larvae spores. The
phage cocktail treatment works by introducing these naturally occurring phages in artificiallyhigh doses to germinating bacteria. AFB is highly infectious within an apiary, typically
spreading to 60-85% of other hives after one hive is infected and, once showing visible
symptoms, an infected hive will collapse without treatment (1,4,12,111). This was true in our
study, where 80% of the control sugar water treated at-risk hives became infected. The efficacy
of phage treatment was pronounced by the fact that 100% of phage-treated at-risk hives were
protected from infection, and 100% of phage-treated sick hives became well.
These studies add to collective knowledge about the safety and efficacy of phage therapy.
This work also demonstrated that the host range observations made in the lab had powerful
correlations to the effectiveness of the field studies. While this publication includes a small
prevention and recovery study, the numbers indicate the power behind using phages for
prophylactic and curative treatments. Future studies are necessary to expand the overall power of
phage treatments for AFB.
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4

CHAPTER 4: “PHAGES USED TO TREAT AMERICAN FOULBROOD BIND TO
VEGETATIVE AND SPORE FORMS OF PAENIBACILLUS LARVAE”

The following manuscript “Phages used to treat American foulbrood bind to vegetative and spore
forms of Paenibacillus larvae” was written and submitted to the Journal of Basic Microbiology,
and is currently under review. The article describes the use of B. laterosporus phages to induce
antibacterial toxins to treat American foulbrood.
References for this manuscript are found in chapter 6 and the in text references to figures
or sections are to those within this chapter.
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Abstract
Paenibacillus larvae endospores are the transmissive agent of the honeybee disease,
American foulbrood. Previous in vivo studies show phage therapy can prevent and control
American foulbrood. Here we present evidence that these phages not only bind to vegetative P.
larvae but also bind to P. larvae spores, which likely contributes to the effectiveness of the
treatment. P. larvae, Brevibacillus laterosporus, Sinorhizobium meliloti, and spores of P. larvae
were each challenged with P. larvae phages. Plaque counts after a Brady Binding Test were
statistically significantly higher from spore samples compared to S. meliloti samples (p =
<0.0001) and negative controls (p = <0.0001). The same bacteria were challenged with FITClabeled phages and fluorescence was measured by flow cytometry to quantify phage binding.
Phage binding in spore samples was not statistically different when compared to phage binding
in vegetative P. larvae (p = 0.5563). Phage binding in both vegetative and spore P. larvae
samples was statistically higher than binding observed in unrelated S. meliloti samples and in
negative control samples. Electron microscopy images of phage-treated spores provide visual
evidence of phages binding to spores similar to that seen on vegetative P. larvae. The
ramifications of spore-binding phages are discussed.
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4.1

Introduction
The spore forming bacterium Paenibacillus larvae causes American foulbrood (AFB) in

honeybees. An AFB outbreak begins when there are too many P. larvae spores in the honey crop
of a nurse bee to be cleared naturally and spores get passed to honeybee larvae (10). In the larval
intestinal tract, P. larvae spores germinate to become vegetative bacteria capable of producing
toxins that liquefy the honeybee larvae (112). The resulting degraded larvae becomes laden with
P. larvae spores which are then tracked to other larvae in the hive by nurse honeybees (1). The
disease spreads quickly within a hive, taking just several days from initial infection to
decimation of a colony (3,8). After the colony collapses, other colonies may rob the
contaminated honey and further spread AFB spores with an 80% transmission rate during an
outbreak in an apiary (82).
Due to their narrow host specificity, phage therapies can target pathogenic bacteria while
leaving commensal bacteria alone. Phage therapy with an appropriate cocktail has proven to be
an effective treatment option for active AFB infections, demonstrating a 100% recovery and
prevention rates in treated hives (82). Furthermore, hives treated with P. larvae phages had no
reinfection of AFB, which may indicate that the phage treatment neutralized latent P. larvae
spores.
We hypothesize that the ability of P. larvae phages to prevent reinfection of AFB is by
specifically binding to the spore form of the bacterium. Phages typically bind to and inject their
DNA into vegetative bacteria, but some phages are known to attach to spores for which they are
specific (47,48). Our data confirm that P. larvae phages can bind to P. larvae spores. Spore
binding was observed in three specific experiments: 1) phages incubated with P. larvae spores
bound to the spores and subsequently created plaques on lawns of P. larvae, 2) bacteria counted
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by flow cytometry generated quantitative data of FITC-labeled phages bound to spores and to
vegetative bacteria in equivalent percentages, and 3) electron microscopy images of phages
bound to the surface of spores.
4.2

Materials and Methods
4.2.1

Spore generation and extraction

Overnight cultures of P. larvae ATCC 9545 grown in ½ x liquid porcine brain and heart
infusion (PBHI) (Acumedia, Lansing, MI) media were grown in a shaking incubator at 37 ºC.
The optical density of the culture was taken to estimate the number of cells per milliliter using
the equation C=A/E where C is colony forming units, A is absorbance at 580 nm, and E is the evalue 6.6 x 10-9. A total of approximately 104 bacterial cells were spread onto tryptic soy and
agar plates with glass beads and allowed to incubate at 37 ºC and 5% CO2 for 8 days. Incubated
plates were doused with five mL of cold sterile ddH2O and allowed to sit for 15 minutes.
Colonies on the plates were gently scraped off the plate and into suspension with sterile loops.
The solutions from eight plates were combined into a 50 mL tube and centrifuged at 12,000 x g
for 20 minutes. Supernatant was poured off and the pellet was resuspended in 40 mL of sterile
ddH2O and centrifuged again as a wash step. The pellet was washed 2 more times. After the last
wash step, the pellet was resuspended in 80% EtOH to kill any remaining vegetative bacteria.
Spores were removed from the ethanol immediately prior to the running of any
experiment to minimize any chances of any spontaneous germination. Spores suspended in
ethanol were centrifuged at 12,000 x g for 5 minutes to pellet the spores and the supernatant
containing alcohol and the dead vegetative cells were discarded with the supernatant. The pellet
was washed three more times using sterile ½ x PBHI broth and then suspended to a
concentration of 104 cfu/mL. Spore purity was also confirmed using the Schaeffer-Fulton
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staining method: briefly, samples were heat fixed, stained with 5% malachite green for five
minutes over heat, and counterstained with 0.2% safranin. (113)
4.2.2

Phage generation

Phages specific for P. larvae were previously isolated and confirmed to infect and lyse
only P. larvae (82) and not B. laterosporus (paper in review). Phage lysate was prepared by
reconstituting the phage from freezer stock by mixing several ice chunks from the stock with 500
µL of overnight P. larvae and plating the solution in ½ x PBHI top agar and left to incubate at 37
ºC. After 24 hours, visible plaques were plucked from the plate, suspended in 25 mL of ½ x
PBHI broth containing 1x106 cfu of P. larvae and incubated, shaking at 37 ºC. After 16 hours the
lysate was filtered through a 0.22 µM vacuum filter (VWR, Radnor, PA).
4.2.3

Phage binding detection using the Brady Binding Test

The Brady Binding Test is designed to identify the ability of a phage to bind to a
bacterium or other item and remain viable against its original target. The test relies on incubating
the phage with the test bacterium, transfering the sample onto a filter, and then rinsing the
trapped bacteria to remove un-bound phages. The trapped, rinsed, bacteria are transferred to
incubate with bacteria of the original phage target and a standard plaque assay is done. The
Brady Binding Test for this study was setup as follows: overnight cultures of P. larvae ATCC
9545, B. laterosporus field isolate B-2, Sinorhizobium meliloti strain B100, and P. larvae ATCC
9545 spores were each diluted to 104 cfu/mL. The bacteria were pelleted, supernatant discarded,
and the pellets resuspended in 1 mL of phage lysate at a titer of 108 pfu/mL, control samples
were resuspended in 1 mL of sterile ½ x PBHI broth, and all samples were set to incubate for 30
minutes at room temperature. Each solution was then poured over its own single use 0.22 µM
vacuum filter to catch all bacteria. The filters were then rinsed with 1 L of 1x phosphate buffered
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solution to wash away any phages that were not bound to the bacteria. The filters were removed,
placed in tubes containing 1 mL of ½ x PBHI broth, and set to vortex on high for 1 hour to
dislodge bacteria from the filter. Of the resulting solutions, 100 µL were incubated 5 or less
minutes with 500 µL of overnight P. larvae ATCC 9545 and then plated in ½ x PBHI top agar.
The resulting plaques were counted.
4.2.4

Determination of non-specific FITC staining on bacterial samples

Staining methods similar to those previously described (114,115) were modified to
fluorescently label phages and observe by flow cytometry. To prevent false positives where an
excess of fluorochromes could bind directly to treated bacteria, the amount of background
staining of FITC was determined for seven concentrations of unconjugated fluorescein
isothiocyanate (FITC). FITC stain at concentrations of 500, 250, 125, 62.5, 31.25, 15.625,
7.8125, and 0 µg/mL was added to P. larvae, B. laterosporus, S. meliloti, and P. larvae spores.
Fluorescence of each sample was then measured by a Cytoflex flow cytometer (Beckman
Coulter, Indianapolis, IN) and positive samples were observed in comparison to samples
containing 0 µg /mL FITC.
4.2.5

Phage binding detection by FITC stain and flow cytometry

Unconjugated FITC was added to a high titer phage lysate suspended in 1x Hepes solution
(pH 7.4) at a concentration of 31.25 µg/mL and allowed to incubate for one hour. The high titer
lysate (1011 pfu) was ultracentrifuged at 25,000 g for one hour to pellet the phages. The
supernatant containing the unbound FITC was poured off and the pellet resuspended in Hepes
solution to where the FITC concentration would be 15.625 µg/mL to prevent background
staining of bacteria. For flow cytometry analysis, bacterial samples were loaded into a 96-well
plate containing approximately 5 x 104 cfu in each well. Each well received 200 µL of FITC
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labeled phages. Cell fluorescence was measured by a Cytoflex flow cytometer and a minimum of
50,000 cells were counted per sample.

Figure 4.1. Gates used to establish positive samples, eliminate debris, and isolate singlets.
The gates used for Paenibacillus larvae samples run on a flow cytometer. Each bacterial type had
slightly different gates due to individual size, granularity, and autofluorescence. (A) Gate
eliminates small and large debris. (B) Gate isolates singlets from the sample to decrease
autofluorecense. (C) FITC histogram of a negative sample, the gate is set at the edge of the
negative peak. (D) FITC histogram of a positive sample, a shift into the positive bracket
indicates a highly positive sample.
4.2.6

Flow cytometry data analysis

Beckman Coulter CytExpert software was used to analyze the flow cytometry data
collected on the Beckman Coulter Cytoflex flow cytometer. Three gates were individually set
using unstained samples of each bacterial type. The gates were set on FSCxSSC to exclude
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debris, FSC-HxFSC-A to isolate singlets, and on the FITC channel to identify positive samples,
see Figure 4.1.
4.2.7

Phage binding detection by electron microscopy

Vegetative P. larvae and P. larvae spores (5 x 105 cfu) were resuspended in 1 mL of 3 x
109 pfu/mL high titer lysate and allowed to incubate for one hour. The phage-treated spores were
pelleted at 8,000 rpm for 6 minutes. The supernatant was poured off and the pellet was
resuspended in 40 µL of 1x hepes solution.
Phage/spore samples were incubated with copper grids for 60 seconds and then incubated
with 50 µL of 2% uranyl acetate (pH 7) for 60 seconds. Moisture was wicked away from the
grids and then allowed to air dry prior to imaging. Electron micrographs were taken by the BYU
Microscopy Center on a Verios STEM machine (81).
4.2.8

Statistics

Data was analyzed using SAS software (SAS Institute Inc., Cary, North Carolina), the
ANOVA algorithim, and the mixed procedure method to generate p-values, standard deviation,
standard error and to determine statistical significance for Figures 4.2, 3, 4, and 5. For direct
count statistics in 3.1, we used Jeffery’s 95% confidence interval (116) for binomial proportions.
For all experiments α=0.05.
4.3

Results
4.3.1

Spores prepared for studies are vegetative-free and viable

Our objective was to establish a bank of viable P. larvae ATCC 9545 spores that was
devoid of vegetative bacteria from which we could pull to perform our experiments. Spore
sample purity was essential to prevent false positive in the experiments performed. All sample
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Figure 4.2. Paenibacillus larvae growth curves ensure the absence of vegetative bacteria in spore
samples.
The optical density was measured for three dilutions of vegetative P. larvae and for P. larvae spores
during a 17-hour incubation in broth that does not allow spore germination. The resulting curves are
normal for samples containing vegetative bacteria and no curve was observed from spore samples.
stocks were independently assessed five times to confirm spore purity using multiple methods as
follows. After spore isolation, samples were diluted and then stained with Malachite green to
verify spore presence and safranin counterstained to identify vegetative bacteria in the sample.
At least 100 cells from each of the five samples were observed and counts taken for the number
of spore versus spores in mother cell versus vegetative cells. No vegetative cells were identified
in the spore samples using this method but an average of 8±2.62% of spores had not released
from their mother cell. Free endospores made up the remaining 92±2.14% of cells counted.
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Spore samples were incubated in ½ x PBHI broth to further confirm the spore purity of
the samples. Spores generated from strain ATCC 9545 do not germinate in liquid media;
therefore, any increase in optical density of an incubated sample would result from vegetative
bacterial growth in the sample. Positive controls of vegetative bacteria were incubated with
starting concentrations of 106, 105, and 104 cfu/mL. Spores had an approximate concentration of
105 cfu/mL. Results of this verification study are presented in Figure 4.2. The optical density of
the spore samples did not change significantly over 17 hours in comparison to the vegetative P.
larvae samples at 106, 105, and 104 cfu/mL over the same amount of time. These data indicate
that the spore samples did not contain any significant amount of vegetative bacteria.
Purified spore samples were further washed and stored in 80% Ethanol until experimental
use as described in the material and methods section. The ethanol wash treatment was also tested
on vegetative P. larvae to verify that the ethanol treatment would kill any surviving vegetative
cells in the spore samples. Killed vegetative cells were pelleted, washed, and resuspended in
broth. Ethanol treated vegetative cells were plated in triplicate and incubated for 48 hours. No
colonies formed from ethanol killed cell samples. Spore samples were also plated for
germination to ensure viability of the spores. After a 48-hour incubation, colonies formed on
spore-inoculated plates and the colonies were confirmed to be P. larvae by catalase test and gram
stain.
4.3.2

Results of the Brady Binding Test indicate that phages bind to spores and related
bacteria

We developed the binding test to directly observe phage binding to bacteria and/or spores
and to verify phage viability after binding, if binding occurs. Bacterial cells were incubated with
a high titer phage lysate and then the bacteria were trapped on a filter for rinsing. After rinsing
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non-bound phages through the filters, the bacteria were resuspended and plated with vegetative
P. larvae. Plates were observed for the formation of plaques.
The phages were challenged with the following bacteria to test for binding: P. larvae
ATCC 9545, B. laterosporus field isolate B-2, S. meliloti strain B100, and P. larvae ATCC 9545
spores. B. laterosporus was selected because of its genetic similarity to P. larvae and S. meliloti
was chosen for its genetic dissimilarity. Vegetative P. larvae treated with phages generated the
greatest amount of plaques, as would be expected, forming 159±10 on average, see Figure 4.3.
However, phages challenged with vegetative B. laterosporus generated the next highest amount
of plaques at an average of 145±9. P. larvae spores generated 132±9 and S. meliloti generated
35±9 plaques on average. Phage-only controls generated 3±10 plaques. The vegetative P. larvae
and B. laterosporus challenges generated numbers of plaques that were not significantly different
from each other (p = 0.1925). Furthermore, the number of plaques between P. larvae spores and
vegetative B. laterosporus (p = 0.2494) were not significantly different. The number of plaques
from P. larvae spores were statistically different from that of vegetative P. larvae (p = 0.0018).
S. meliloti samples were significantly different from all other samples (p = <0.0001).
This binding assay uses a short incubation period and a filter rinse of the bacteria prior to
a plaque assay. Plaques indicate that binding to the challenge bacteria occurred during the first
step. Phages that bind can either infect the bacteria they are challenged with during the first step
and then produce plaques on their intended host in the plaque assay, or the phages can exhibit
reversible binding wherein the phages bind to the challenge bacteria in the first step and release
to infect and produce plaques on their intended host in the plaque assay.
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The results in Figure 4.3 suggest that high levels of P. larvae phage binding occurs to
vegetative and spore forms of P. larvae. In addition, phages bind at high levels to vegetative B.
laterosporus and exhibit a very low amount of binding to S. meliloti. S. meliloti is not related to

Figure 4.3. Brady Binding Test results indicate that phages bind to P. larvae bacteria and spores, and to B.
laterosporus bacteria.
Phages were challenged for binding with four bacterial types and unbound phages were rinsed away.
Resultant samples were plated with vegetative P. larvae and incubated overnight for phage infection and
plaque development. Plaques were counted and averaged per plate. All samples where phages were
challenged with bacteria were statistically different from the phage only control.
* P. larvae and B. laterosporus were statistically different from the controls (p = <0.0001) and not from each
other (p = 0.1925).
† B. laterosporus and P. larvae spores were statistically different from the controls (p = <0.0001) and not
from each other (p = 0.2494).
‡ S. meliloti was statistically different from all other samples (p = <0.0001).
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P. larvae, so the low level of phage binding to S. meliloti was not unexpected. Binding of phages
to B. laterosporus was surprising because the P. larvae phage used for this study is one that we
extensively tested on multiple strains of bacteria and is specific for P. larvae and does not infect
any of our tested strains of B. laterosporus (unpublished). Binding of B. laterosporus by the
phages seems to be happening at a similar rate as that of it binding to vegetative P. larvae. Such
binding suggests a reversible binding site of the phages to some cell wall component shared
between P. larvae and B. laterosporus. Furthermore, plaques appeared on plates within 24 hours
and yet a spore would take approximately 48 hours or more to germinate, which suggests that the
plaques from the phages challenged with P. larvae spores are also likely due to reversible
binding off of the spore and onto the vegetative cells used in the plaque assay.
4.3.3

FITC can be observed on bacteria at high concentrations and should be diluted if used
for flow cytometry detection of phage binding

Puapermpoonsiri et al. published the use of unconjugated FITC to stain phages for
fluorescent confocal scanning microscopy (115), and used a concentration of 250 µG/mL. We
decided to modify their protocol slightly and use flow cytometry to obtain a quantitative
assessment of phage binding to bacteria and spores. First, we needed to determine whether the
FITC would also stain bacteria, and if a threshold level could be identified of background
staining on bacteria below which we could still stain and detect phages. This study was designed
to reduce false positive readings by identifying the concentration of free-FITC that would no
longer make bacteria fluoresce. By knowing this limit, we could stain our phages at a higher
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concentration, then wash and dilute the phages to a lower concentration and thereby prevent
direct FITC binding to the bacterial samples. FITC at concentrations of 500, 250, 125, 62.5,
31.25, 15.625, 7.8125, and 0 µG/mL were added to P. larvae, B. laterosporus, S. meliloti, and P.
larvae spores, each at an approximate concentration of 5 x 104 cfu/mL, see Figure 4.4. Each
bacterial sample fluoresced when dosed with 500 µG/mL. B. laterosporus fluoresced to a

Figure 4.4. FITC stain can be diluted to a concentration below where bacteria will absorb detectable
stain directly.
Bacterial samples were dosed with seven FITC concentrations to determine fluorescence of bacteria
labeled directly. Samples were compared to untreated groups to establish a positive range. All bacteria
stopped fluorescing when dosed with 15.625 µg/mL or less FITC.
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significant degree at concentrations of 250 and 125 µG/mL. Spores fluoresced at staining
concentrations down to 31.25 µG/mL. From this data, we determined that bacteria should not be
exposed to more than 31.25 µG/mL for the purpose of identifying phage binding.
4.3.4

Results of flow cytometry studies indicate that phages bind to spores and related
bacteria

A flow cytometer reads single-cells and reports the fluorescence intensity of each
individual bacterium. The flow cytometer can rapidly count and report fluorescence results of

Figure 4.5. Flow cytometry results detect phages bound to bacteria and spores.
Bacteria and spores were incubated with FITC-labeled phages. Fluorescence of the cells was measured
via flow cytometry and positive cells were reported as a percentage of the total population of bacteria
in the sample. Negative controls (in FITC stain without phages), were low and all samples with phages
were statistically significant compared to the controls excluding S. meliloti (p = 0.2494).
* P. larvae, B. laterosporus, and P. larvae spores were statistically different from their controls (p =
<0.0001; 0.0084; 0.0017) and not from each other.
† B. laterosporus and S. meliloti were not significantly different from each other (p = 0.3297).
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thousands of individual cells in a sample. Phages were first stained with FITC and then incubated
with challenge bacteria and analyzed by flow cytometry to identify binding according to
fluorescence. Positive and negative regions on the histogram for FITC were determined
according to results of the negative control samples treated with FITC without phages for each
bacterium with a minimum of 50,000 cells analyzed by flow cytometry per sample. Figure 4.1
shows how flow cytometry data was analyzed and gives an example of a bacterial sample
lacking phages (Figure 4.1C) and an example of a bacterial sample with phages attached (Figure
4.1D). FITC-stained phages were challenged with vegetative P. larvae, B. laterosporus, S.
meliloti, and spores of P. larvae. The average percentage of FITC-positive bacterial cells for
each of these samples is reported in Table 4.1.
Table 4-1. Percent of positive fluorescence on FITC histogram.
Percent fluorescence of untreated and phage-treated bacterial samples.
% FITC-positive Bacteria
Negative Control

Phage Treated

Vegetative P. larvae

5±20%

76±14%

P. larvae spores

5±20%

57±14%

Vegetative B. laterosporus

2±20%

48±14%

Vegetative S. meliloti

5±20%

26±14%

As indicated in Figure 4.5, P. larvae (p = <0.0001), B. laterosporus (p = 0.0084), and P.
larvae spores (p = 0.0017) treated with labeled phages are significantly different from untreated
samples where S. meliloti treated with phages did not have a statistical difference from an
untreated sample (p = 0.6513). These data support the results of the Brady Binding Test because
phages were observed to bind to vegetative and spore P. larvae, as well as to B. laterosporus,
and not to S. meliloti. The results also confirm that FITC staining and flow cytometry can be
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used to observe quantitative differences in phage binding to bacteria.
4.3.5

Electron microscopy yielded images of phages attached to spores

The objective of electron microscopy was to capture visual evidence of the reported
results in sections 3.2 and 3.4. Spores treated with phages were imaged using a Verios STEM
machine on formvar coated copper grids. Figure 4.6a is an image of vegetative P. larvae treated
with phages. The arrows on the left of the micrograph show phage tails without capsids bound at
a slant to the cell wall of the bacterium. The arrows to the right indicate intact phages; one phage
is about to attach to the bacterium, one is attached to the cell surface at a slant, and one phage is
attached and erect on the cell. Figures 4.6b and 4.6c show phages bound to P. larvae spores.
Figure 4.6b shows phages bound at a slant to the spore and Figure 4.6c shows phages erect on
the surface of the spore. Electron microscopy studies by others indicate that phages can bind in a
slanted orientation and then move upright for injection (117). Both horizontal and vertical
binding was apparent in our electron microscopy samples. The alternative phage orientation on
the bacterium and spores in our images may indicate differences between reversible and

Figure 4.6. STEM images of phages bound to vegetative and spore form Paenibacillus larvae.
(A) Arrows pointing to phages (right) and phage tails bound (left) in several orientations in
relationship to the vegetative bacterial cell. (B) Arrows indicate and box show phages bound to the
surface of a spore at a slanted position to the spore. (C) Arrows point to two phages bound to the
surface of a spore in an upright orientation to the spore.
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irreversible binding, and/or may indicate that DNA injection occurs with both the vegetative and
spore forms of P. larvae.
4.4

Discussion
Pure spores are vital for any study that will involve a comparison between responses in

spores versus responses in vegetative bacteria. Eliminating vegetative bacteria and reducing
endospores residing in mother cells that could have vestigial receptors for phage binding was
paramount to the experiments we conducted to prevent phages binding to vegetative cell wall
proteins and producing false positives. The spores were inert in liquid media meaning that they
did not germinate when put into nutrient broth and thus they did not generate vegetative cell
membrane proteins. Collected spores were found to be clear of vegetative cells, but did contain a
small percentage of spores that had not exited the mother cell and thus may contain small
amounts of vegetative cell receptors to which phages could bind. This likelihood is not great due
to small number of unreleased endospores were found especially because In the electron
microscopy images no cells were identified that were still within mother cells. Further, spore
samples run through the flow cytometer were gated to exclude doublets and endospores
remaining inside of mother cells should show up as much larger cells much as a doublet would
appear.
Detecting phage binding with fluorescence is an exciting new tool to quantify the binding
potential of phages to target and non-target bacteria. In these studies, FITC-labeled phages act
like large fluorescently labeled antibodies, creating a positive peak on a flow cytometer when
bound to bacteria. Our findings indicate a low level of off-target binding of P. larvae phages to
S. meliloti and moderate levels of off-target binding to B. laterosporus. Similar levels of phage
binding to its target vegetative and spore bacteria were also seen showing that the P. larvae
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phage used in these studies bind equally to both bacterial states. An excess of fluorochrome in
solution with labeled phages leads to direct background staining of bacteria. Unconjugated FITC
covalently bonds to primary amines and sulfhydryls via standard NHS isothiocyanate chemistry.
Phages incubated with FITC are not individually detected via flow cytometry because they are to
too small. However, When several phages are bound to the surface of a bacterium the phages’
collective fluorescence is read as the bacterial cells’ own fluorescence. The results of the
background tests allowed us to identify at what concentrations we could label our phages with
FITC without worrying about background interference. Spores stained the strongest during our
background tests did not stain the strongest during phage binding experiments. Similarly,
vegetative P. larvae was did not stain strongly during background stain experiments but was the
most fluorescent during phage binding tests. These results suggest that phage binding is cause of
the fluorescence measured and not due to background FITC staining of bacterial samples.
The Brady Binding Test is a new method that can be used to detect viable phage binding
to target and non-target bacteria. P. larvae phages bound to the four tested bacterial types
generated plaques in lawns of P. larvae suggesting phage binding to target and off-target bacteria
and spores. The low amount of binding seen with S. meliloti in 3.2 could be explained by phages
being trapped on top of or in between the bacteria and no actual binding occurred. The
differences between P. larvae and S. meliloti could mean that reversible binding sites on the
phage tail did not have a strong interaction with the S. meliloti cell wall. In either case, P. larvae
phages seem to bind to P. larvae spores as well as to B. laterosporus, the close relative to P.
larvae. These results are surprising because the phages do not cause plaques on lawns of B.
laterosporus but create similar amounts of plaques to P. larvae challenged with phages. This
may be explained by a reversible binding site located on the close relative, B. laterosporus,
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which allows the phages to attach to the bacterium but lack critical irreversible binding sites for
the phage. Baptista et. al presented findings about the siphovirus SPP1, showing that the phage
reversibly binds to the cell wall teichoic acid before irreversibly binding to the YueB protein on
Bacillus subtilis (118,119).
Our data supports what we have seen in field studies where AFB infected hives were
treated with P. larvae phages. In those previous studies the hives recovered in less than two
weeks and did not become reinfected (82). P. larvae phages that bind to P. larvae spores and B.
laterosporus in a reversible fashion as seen in 3.2 could account for the long term protection
phage therapy lends to hives. By having reversible binding sites on spores and B. laterosporus
the phages increase their likelihood of coming into contact with vegetative P. larvae as the
spores germinate or B. laterosporus expands as a secondary infection to AFB.
Electron microscopy images show phages bound to the surface of spores in various
orientations suggesting interesting possibilities for the P. larvae spore/phage relationship. Other
researchers using cryotomography on T4 phages revealed different phage orientations during the
infection process. Their data suggests that long tail fibers bind to target bacteria first and the
strain from the bound tail fibers triggers the release of short tail fibers from the baseplate, leaving
the phage to the side of the bacteria. Then, short tail fibers bind to specific receptors on the
surface of the bacteria, which erects the phage and triggering the injection of DNA into the cell
(117,120,121). Figure 4.6a shows phages bound to the surface of vegetative P. larvae bacteria
shows phages in two orientations in relation to the bacteria similar to those described in previous
research. Both orientations are also seen in Figures 4.6b and 4.6c where phages are bound to the
surface of P. larvae spores. P. larvae phages may have a similar infection initiation as evidenced
by images of phages bound to vegetative cells and spores. If the erect phages have bound to their
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secondary target and ejected DNA into the cell, then P. larvae phages may be able to directly
infect P. larvae spores similar to other spore infecting phages (48).
Our findings show a relationship between the spore form of P. larvae and one of its
phages. Although this study did not show that the phage directly killed spores, other phages have
been biopanned to do just that (48). By hunting for phages that specifically target and destroy
spores, phage cocktail therapies have a greater potential for functionality because of the likely
ability to prevent recurrent infections caused by spores.
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CONCLUSION
Due to the emergence of antibiotic resistance, phage therapies are becoming an
increasingly more attractive treatment method for bacterial infections. This study explored two
phage therapy types that can be employed in the treatment of AFB. It was shown that B.
laterosporus phages can infect and induce toxin production in B. laterosporus. When AFB
infected hives were treated with B. laterosporus phages, 75% of the hives recovered. It was also
seen that the recovered hives relapsed with AFB after the completion of treatment indicating that
the toxins produced by B. laterosporus do not neutralize the spore form of P. larvae. The second
phage therapy described in this work was comprised of P. larvae phages. The P. larvae phage
therapy showed no detrimental effect on hives, whereas the antibiotic control group experienced
reduced hive health. Further, the phage therapy proved to be 100% effective at clearing and
preventing AFB. P. larvae phage therapy treated hives never relapsed with AFB which suggests
that the phages not only killed vegetative bacteria but also neutralized spores remaining in the
hive. An investigation was launched into the relationship between the P. larvae phages and P.
larvae spores to understand the full effectiveness of P. larvae phage therapy. Several assays were
developed to gather evidence of phage binding to spores. It was seen that phages bind to spores
and are able to produce plaques when plated onto vegetative P. larvae. Furthermore, a modified
method to label phages with FITC was developed to quantify phage binding to target bacteria by
using flow cytometry. We observed similar FITC fluorescence between vegetative and spore
forms of P. larvae when treated with labeled P. larvae phages while there was not a significant
shift for samples of unrelated S. meliloti vegetative bacteria treated with labeled phages. STEM
images also showed phages binding to P. larvae spores.
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The findings of this research provide strong evidence that phages bind to and neutralize
P. larvae spores. These results are exciting as they suggest that phages could potentially be used
to decontaminate tools or hive boxes contaminated with P. larvae spores. Phages that bind to the
spore form P. larvae may be evolutionarily favored due to the AFB infection cycle. AFB is
caused by nurse bees inadvertently feeding P. larvae spores to larval honeybees and P.
larvae spores, the infectious agents of AFB, only germinate in the gut of larval honeybees after
their cells are capped. After liquefying the pupil larvae, the vegetative P. larvae sporulate. By
binding to spores, naturally lytic P. larvae phages are more likely to encounter vegetative P.
larvae after spore germination. Furthermore, the data shows reversible binding to B. laterosporus
as well as to spores. B. laterosporus is a commensal in many beehives and could act as a reserve
for P. larvae phages in the gut of honeybees. This work also provides foundational precedence
for treating infections with bystander phage therapy. By inducing toxins in nearby bacteria, this
method could be taken in many directions for treating a broader range of bacterial, fungal, or
parasitic infections.
My contributions to the field of phage research development of lab / research proposed
new hypothesis 1) bystander phage therapy, two new protocols, 2) Brady Binding Test, and 3)
flow cytometry for phage binding. For applied sciences, in vivo studies where 1) phage safety
information & antibiotic use, 2) phage treatment and prevention of AFB, observational
differences between treatments that affect spores (i.e. bystander doesn’t kill spores, direct phage
treatment does).
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